探讨布地奈德福莫特罗联合噻托溴铵对中重度稳定期COPD患者肺功能的影响  

Investigation of the Effect of Budesonide Dermotam Combined with Tiotropium Bromide on Pulmonary Function in Patients with Moderate to Severe Stable Phase COPD

作　　者：贾嵘[1] 郭艳艳[1] 刘磊[1] 

机构地区：[1]连云港市第二人民医院急诊科,江苏连云港222000

出　　处：《中外医疗》2017年第23期1-3,共3页China & Foreign Medical Treatment

摘　　要：目的探讨布地奈德福莫特罗联合噻托溴铵对中重度稳定期COPD患者肺功能的影响。方法根据前瞻性研究原则,方便选取该院2010年5月—2015年6月期间收治的48例中重度稳定期COPD患者,随机分为对照组和观察组,每组24例。对照组患者单纯给予噻托溴铵治疗,观察组在对照组基础上联合使用布地奈德福莫特罗治疗。评价两种方法的治疗效果,同时比较两组患者治疗前后肺功能各项指标的改善情况、治疗过程中两组患者的不良反应发生情况。结果观察组患者治疗总有效率为91.67%显著高于对照组79.17%(P<0.05)。观察组患者治疗后FEV1(2.3±0.1)L及FVC(3.2±0.5)L、FEV/FVC(83.4±13.4)%显著优于治疗前(1.1±0.2)L、(2.3±0.4)L、FEV/FVC(63.2±18.2)%,对照组治疗后FEV1(1.5±0.4)L及FVC(2.7±0.4)L、FEV/FVC(70.1±15.2)%显著优于治疗前(1.1±0.3)L、(2.2±0.5)L、FEV/FVC(63.8±20.1)%(P<0.05)。且观察组患者治疗后各项指标均显著优于对照组(P<0.05)。观察组不良反应发生率12.50%与对照组8.33%比较,差异无统计学意义(P>0.05)。结论布地奈德福莫特罗联合噻托溴铵治疗中重度COPD的效果较好,不但不良反应较少,且能帮助患者改善肺功能,安全性更高,值得推广。Objective This paper tries to investigate the effect of budesonide dermotam combined with tiotropium bromide on pulmonary function in patients with moderate to severe COPD. Methods Convenient selection According to the prospective study principle, 48 patients with moderate to severe COPD received in this hospital from May 2010 to June 2015 were randomly divided into the control group and the observation group, with 24 cases in each group. The patients in the control group were treated with tiotropium alone, and the observation group added budesonide dermotam treatment. The therapeutic effects of the two methods were evaluated, and the improvement of lung function before and after treatment was compared between the two groups. The adverse reactions in the two groups during the treatment were compared. Results The total effective rate of the observation group was 91.67%, significantly higher than that of the control group of 79.17%（P〈0.05）. The FEV1, FVC, FEV/FVC of the observation group after treatment were（2.3 ±0.1） L,（3.2 ±0.5） L,（83.4 ±13.4）%, significantly higher than that before treatment of（1.1±0.2） L,（2.3±0.4） L,（63.2±18.2）%; the FEV1, FVC, FEV/FVC in the control group after treatment were（1.5±0.4） L and（2.7±0.4） L,（70.1±15.2）%, significantly higher than that before treatment of（1.1±0.3）L,（2.2±0.5） L,（63.8±20.1）%,（P〈0.05）. The indexes in the observation group were significantly better than those in the control group（P〈0.05）. The incidence of adverse reactions was 12.50% in the observation group and 8.33% in the control group（P〉0.05）. Conclusion The effect of budesonide dermotam combined with tiotropium in the treatment of moderate to severe COPD is remarkable, with fewer adverse reactions as well as helping patients improve lung function, and high safety, therefore it is worth promotion.

关 键 词：布地奈德福莫特罗 噻托溴铵 COPD 肺功能指标 

分 类 号：R5[医药卫生—内科学]